Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.42 |
| ▸ | PPARA | Q07869 | 6/20 | 0.42 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | WEE1 | P30291 | 1/20 | 0.36 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13249789 | 0.92 | PPARG (0.42) | PPARGPPARAPTGDR2TSHRGAA | |
| SCHEMBL13328898 | 0.92 | TSHR (0.45) | MTHFD2TSHRGAACCR5WEE1 | |
| SCHEMBL13328919 | 0.89 | KDR (0.47) | PTGDR2 | |
| SCHEMBL13328901 | 0.89 | PPARG (0.41) | PPARGPPARAMTHFD2TSHRGAA | |
| SCHEMBL13328900 | 0.88 | MTHFD2 (0.39) | MTHFD2PTGDR2TSHRGAACCR5 | |
| SCHEMBL13328904 | 0.88 | MTHFD2 (0.39) | PPARGPPARAMTHFD2PTGDR2TSHR | |
| SCHEMBL13328912 | 0.88 | MTHFD2 (0.41) | PPARGMTHFD2TSHRGAACCR5 | |
| SCHEMBL13328838 | 0.87 | MTHFD2 (0.42) | MTHFD2PTGDR2CCR5PDE10A | |
| SCHEMBL13328897 | 0.87 | CCR5 (0.44) | MTHFD2TSHRCCR5PDE10A | |
| SCHEMBL13328941 | 0.87 | MTHFD2 (0.41) | MTHFD2TSHRGAACCR5WEE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318751-B2 | Pyrimidinone derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318751-B2 | Pyrimidinone derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20100113487-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2010-05-06 | — | — | US | disclosed |
| US-20100113487-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113487-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GPR180, GPR17 | PPARG 26/4885PPARA 35/4885MTHFD2 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.